Labshake search
Citations for BioLegend :
51 - 100 of 1138 citations for Recombinant Rat Cd86 His tagged since 2019
Citations are collected from bioRxiv only, the total number of publications could be much larger.
-
bioRxiv - Neuroscience 2023Quote: ... BV650 anti-CD86 (Biolegend, 105035), BV785 anti-CD86 (Biolegend ...
-
bioRxiv - Bioengineering 2023Quote: ... CD86 (AF700, Cat#105024, BioLegend), CD86 (BUV395 ...
-
bioRxiv - Immunology 2024Quote: ... CD86-PeDazzle594 (Biolegend, Clone:GL-1), IgM BUV615 (BD ...
-
bioRxiv - Immunology 2024Quote: ... CD86-AF700 (Biolegend, Clone:GL-1), CD86-PeDazzle594 (Biolegend ...
-
bioRxiv - Cancer Biology 2024Quote: ... Alex488-anti-CD86 (BioLegend, 374203), Alex488-anti-CD80 (BioLegend ...
-
bioRxiv - Cell Biology 2019Quote: ... anti-CD86-BV650 (GL-1, Biolegend), anti-CD80-PE-Dazzle (16-10A1 ...
-
bioRxiv - Immunology 2021Quote: ... including CD80 or CD86 antibodies (BioLegend), and acquired by a BD LSR II flow cytometer (BD Biosciences) ...
-
bioRxiv - Cell Biology 2021Quote: ... anti-mouse CD86 APC (Biolegend, 105012), or anti-mouse CD324 biotin (E-cadherin ...
-
bioRxiv - Immunology 2022Quote: ... CD86 (GL-1, AF647, BioLegend, 105020). Zombie NIR Fixable Viability Kit was purchased from BioLegend (423106) ...
-
bioRxiv - Immunology 2022Quote: ... CD86-PE/Cy5 (GL-1, Biolegend), MHC-II-PE/Cy7 (M5/114.15.2 ...
-
bioRxiv - Immunology 2022Quote: ... CD86 (BV785, clone: GL-1, BioLegend), IFNγ (BV711 ...
-
bioRxiv - Cancer Biology 2022Quote: ... anti-CD86 (clone GL-1, Biolegend), anti-CD146 (clone ME-9F1 ...
-
bioRxiv - Immunology 2022Quote: ... and CD86 (BioLegend clone GL-1) at 4°C for 25 minutes ...
-
bioRxiv - Microbiology 2021Quote: ... PE-conjugated anti-CD86 (IT2.2, Biolegend), polyclonal Alexa647-conjugated goat anti-chicken IgY (Abcam) ...
-
Monocyte reconstitution and gut microbiota composition after hematopoietic stem cell transplantationbioRxiv - Immunology 2019Quote: ... CD86-PE-Cy7 (clone lT2.2; BioLegend), CD15-Pacific Blue (clone Hl98 ...
-
bioRxiv - Neuroscience 2022Quote: ... and anti-CD86 (GL-1, Biolegend). Cells were washed twice and fixed in fixation buffer (Biolegend) ...
-
bioRxiv - Immunology 2022Quote: ... CD86 (clone GL-1, BioLegend, 105013), CD62L (clone MEL-14 ...
-
bioRxiv - Cancer Biology 2023Quote: ... Antibodies used were CD86 (Biolegend, 105037), F4/80 (Biolegend 123141) ...
-
bioRxiv - Bioengineering 2023Quote: ... BV421 CD86 (1:200, Biolegend, 105031), APC CD206 (1:200 ...
-
bioRxiv - Immunology 2023Quote: ... APC anti-human CD86 (374207, Biolegend), PE anti-human CD80 (305208 ...
-
bioRxiv - Immunology 2023Quote: ... PerCP.Cy5.5-anti-CD86 (clone 374216, Biolegend), FITC-anti-CD83 (clone HB15e ...
-
bioRxiv - Immunology 2024Quote: ... CD86 (BioLegend, #105012, clone GL-1), Langerin (BioLegend ...
-
bioRxiv - Immunology 2023Quote: ... anti-human CD86 (clone BU63, BioLegend), anti-human PD-L1 (clone 29E2A3 ...
-
bioRxiv - Cancer Biology 2021Quote: ... PerCP-conjugated anti-mouse CD86 (105025, BioLegend) and FITC-conjugated anti-mouse CD40 (124607 ...
-
bioRxiv - Cell Biology 2019Quote: ... and CD86 (105001) were obtained from Biolegend. AcLDL (L23380) ...
-
bioRxiv - Immunology 2021Quote: ... CD86 (Clone GL-1, BioLegend, Cat 105026), and CD8 (Clone 53-6.7 ...
-
bioRxiv - Microbiology 2020Quote: ... anti-CD86 (2µg/ml, GL-1; Biolegend), anti-Ly6G (1µg/ml ...
-
bioRxiv - Microbiology 2020Quote: ... Cell surface with CD86-Bv711 (IT2.2, Biolegend) and HLA-DR-PerCpCy5.5 (L243 ...
-
bioRxiv - Immunology 2022Quote: ... and APC anti-mouse CD86 (105011, Biolegend) were used to stain the cells in flow cytometry staining (FACS ...
-
bioRxiv - Microbiology 2019Quote: ... CD86 APC (clone GL-1; BioLegend, 105012), CD86 PE/Cy5 (clone GL-1 ...
-
bioRxiv - Immunology 2021Quote: ... CD86 (BV605, Biolegend, 1:200, clone GL1), PD-1 (PE-Cy7 ...
-
bioRxiv - Bioengineering 2022Quote: ... and CD86 BV421 (clone GL-1, Biolegend). Stained cells were analyzed using an LSR Fortessa flow cytometer (BD Biosciences).
-
bioRxiv - Bioengineering 2022Quote: ... FITC anti-mouse CD86 antibody (Biolegend 105005), APC anti-mouse CD11c antibody (Biolegend 117309) ...
-
bioRxiv - Bioengineering 2023Quote: ... CD86 (BV785, clone: GL1, BioLegend, cat: 105043), GL7 (AF488 ...
-
bioRxiv - Immunology 2023Quote: ... CD86 (BV605, Biolegend, 1:200, clone GL1), PD-1 (PE-Cy7 ...
-
bioRxiv - Immunology 2023Quote: ... anti-CD86 (1:300; A647; BioLegend #105020), anti-Siglec-F (1:400 ...
-
bioRxiv - Systems Biology 2023Quote: ... CD86- PE-Dazzle 594 (BioLegend, Cat# 105042), CD206-PE (BioLegend ...
-
bioRxiv - Immunology 2023Quote: ... TotalSeq-A-labeled CD86 (GL-1, BioLegend), TotalSeq-A-labeled MHC II (M5/114.15.2 ...
-
bioRxiv - Immunology 2023Quote: ... anti-human CD86-BV785 (clone IT2.2, BioLegend), anti-human CD95-BUV737 (clone DX2 ...
-
bioRxiv - Immunology 2024Quote: ... PerCP-Cy5.5-CD86 (Clone GL-1, BioLegend), PE-Cy7-CD11c (Clone N418 ...
-
bioRxiv - Bioengineering 2023Quote: ... BV421 CD86 (1:200, Biolegend, cat#105031), APC CD206 (1:200 ...
-
bioRxiv - Immunology 2023Quote: ... PE-Cy7-conjugated anti-CD86 (PO3) (BioLegend), BUV395-conjugated anti-CD11b (M1/70 ...
-
bioRxiv - Cancer Biology 2024Quote: ... APC-conjugated CD86 (1:100, 105011, Biolegend); Panel 4 ...
-
bioRxiv - Bioengineering 2020Quote: ... and APC/Fire 750 anti-mouse CD86 (BioLegend) was added to the cells and incubated for 20 minutes at 4 °C ...
-
bioRxiv - Cell Biology 2020Quote: ... APC-anti-mouse CD86 (clone GL-1, Biolegend), FITC-anti-mouse CD206 (clone C068C2 ...
-
bioRxiv - Immunology 2020Quote: ... CD86-PE (GL-1, Biolegend, San Diego CA), CXCR4-APC (L276F12 ...
-
bioRxiv - Microbiology 2019Quote: ... CD86 PE/Cy5 (clone GL-1; BioLegend, 105016), Ly-6G/Ly-6C (Gr-1 ...
-
bioRxiv - Immunology 2020Quote: ... anti-human CD86 APC (BioLegend, San Diego, CA), and antihuman CD206 FITC (BioLegend) ...
-
bioRxiv - Immunology 2022Quote: ... and anti-CD86-PE (clone GL-1, BioLegend), respectively ...
-
bioRxiv - Cancer Biology 2022Quote: ... APC-CD86 (BioLegend Cat# 105012, RRID:AB_493342; 1:100). Gating strategy for immune subpopulations is shown in supplementary figure 1A-B ...